title: Durable remission after the administration of rituximab for EBV-negative, diffuse large B-cell lymphoma following autologous peripheral blood stem cell transplantation for angioimmunoblastic T-cell lymphoma.
authors.forename: Akihito
authors.initials: A
authors.lastname: Shinohara
authors.forename: Takashi
authors.initials: T
authors.lastname: Asai
authors.forename: Koji
authors.initials: K
authors.lastname: Izutsu
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Ota
authors.forename: Kengo
authors.initials: K
authors.lastname: Takeuchi
authors.forename: Akira
authors.initials: A
authors.lastname: Hangaishi
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Kanda
authors.forename: Shigeru
authors.initials: S
authors.lastname: Chiba
authors.forename: Toru
authors.initials: T
authors.lastname: Motokura
authors.forename: Mineo
authors.initials: M
authors.lastname: Kurokawa
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000235:genetics; D004854:Herpesvirus 4, Human / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000150:complications / Q000628:therapy; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000209:etiology / Q000821:virology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000209:etiology / Q000821:virology; D016411:Lymphoma, T-Cell, Peripheral / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000188:drug therapy / Q000209:etiology / Q000821:virology; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects*; D012074:Remission Induction; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D004279:DNA, Viral; D000069283:Rituximab